Dr. Gottlieb joined Pfizer’s board two months after resigning from the FDA. He held the top post at the FDA for two years. Throughout his tenure he became known for cracking down on the e-cigarette industry and trying to get a handle on the opioid crisis.
In defending his decision to jump to Pfizer, Dr. Gottlieb said before joining the FDA he held several roles in the biotech and pharmaceutical industry.
“I worked with some large drugmakers before I came into the agency,” Dr. Gottlieb told CNBC. “I made no bones about the fact that I had expertise in life sciences and I made my living trying to promote innovation in this sector prior to coming to the agency.”
Since leaving the agency, beyond joining Pfizer’s board, Dr. Gottlieb has returned to work at the American Enterprise Institute as a resident fellow and serves as a partner at a venture capital firm.
Read the full report here.
More articles on pharmacy:
Walmart cutting some pharmacy jobs
UPMC acquires community pharmacy in Pittsburgh
Oklahoma judge approves Teva’s $85M opioid settlement
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.